{"id":56436,"date":"2026-02-05T21:08:39","date_gmt":"2026-02-05T13:08:39","guid":{"rendered":"https:\/\/flcube.com\/?p=56436"},"modified":"2026-02-05T21:08:41","modified_gmt":"2026-02-05T13:08:41","slug":"everest-medicines-licenses-micots-mt1013-for-secondary-hyperparathyroidism-in-178m-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56436","title":{"rendered":"Everest Medicines Licenses Micot\u2019s MT1013 for Secondary Hyperparathyroidism in $178M Deal"},"content":{"rendered":"\n<p><strong>Everest Medicines Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1952:HKG\">HKG: 1952<\/a>) announced a licensing agreement with <strong>Micot<\/strong>, a polypeptide NME drug developer, securing <strong>exclusive commercialization rights<\/strong> to <strong>MT1013<\/strong> in <strong>China and the Asia\u2011Pacific region (excluding Japan)<\/strong>. The first\u2011in\u2011class dual\u2011target peptide targets <strong>calcium\u2011sensing receptor (CaSR)<\/strong> and <strong>osteogenic growth peptide (OGP) receptor<\/strong> for <strong>secondary hyperparathyroidism (SHPT)<\/strong> treatment.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-financial-terms\">Deal Structure &amp; Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>Micot (polypeptide NME developer)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Everest Medicines Limited (1952.HK)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>MT1013 (dual\u2011target peptide)<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>China and Asia\u2011Pacific (excluding Japan)<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>RMB\u202f200\u202fmillion (USD\u202f28.8\u202fmillion)<\/td><\/tr><tr><td><strong>Milestone Potential<\/strong><\/td><td>Up to RMB\u202f1.04\u202fbillion (USD\u202f149\u202fmillion)<\/td><\/tr><tr><td><strong>Development Costs<\/strong><\/td><td>Micot bears clinical development expenses<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td>Phase\u202fIII in China ( &gt;50% enrolled)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Secondary hyperparathyroidism (SHPT) in chronic kidney disease patients on hemodialysis<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-clinical-advantage\">Drug Profile &amp; Clinical Advantage<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> Dual targeting of <strong>CaSR<\/strong> and <strong>OGP receptor<\/strong> provides fast\u2011acting, potent, and durable control of parathyroid hormone (PTH), calcium, and phosphorus<\/li>\n\n\n\n<li><strong>Clinical Data:<\/strong> Phase\u202fIII studies show MT1013 is <strong>well\u2011tolerated<\/strong> with potential to <strong>surpass existing therapies<\/strong> in comprehensive target achievement rates (iPTH, blood calcium, and phosphorus), calcification control, and cardiovascular benefits<\/li>\n\n\n\n<li><strong>Market Need:<\/strong> SHPT affects <strong>~50%<\/strong> : of dialysis patients; current therapies (cinacalcet, etelcalcetide) have limitations in efficacy and tolerability<\/li>\n\n\n\n<li><strong>First\u2011in\u2011Class:<\/strong> First dual\u2011target peptide for SHPT, offering a novel mechanism of action<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China SHPT Market:<\/strong> Valued at <strong>\u00a58\u202fbillion<\/strong> : (~US$1.1\u202fbillion) in 2025, growing at <strong>10% CAGR<\/strong> driven by expanding dialysis population<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u00a52\u20133\u202fbillion<\/strong> (US$280\u2013420\u202fmillion) peak annual sales in China\/APAC by 2028 if approved<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Strengthens Everest\u2019s metabolic and renal disease portfolio; leverages existing commercial infrastructure in dialysis centers<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Phase\u202fIII trial completion expected <strong>H2\u202f2026<\/strong>; NDA submission targeted for <strong>2027<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and revenue projections for MT1013. Actual results may differ due to clinical trial outcomes, competitive dynamics, and NMPA review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020500164_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026020500164_c.\"><\/object><a id=\"wp-block-file--media-d755faef-136b-490a-b65f-3999315d27a0\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020500164_c.pdf\">2026020500164_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020500164_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-d755faef-136b-490a-b65f-3999315d27a0\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Everest Medicines Limited (HKG: 1952) announced a licensing agreement with Micot, a polypeptide NME drug&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[126,1164,4205,25],"class_list":["post-56436","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-everest-medicines","tag-hkg-1952","tag-micot","tag-potential-first-in-class"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Everest Medicines Licenses Micot\u2019s MT1013 for Secondary Hyperparathyroidism in $178M Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Everest Medicines Limited (HKG: 1952) announced a licensing agreement with Micot, a polypeptide NME drug developer, securing exclusive commercialization rights to MT1013 in China and the Asia\u2011Pacific region (excluding Japan). The first\u2011in\u2011class dual\u2011target peptide targets calcium\u2011sensing receptor (CaSR) and osteogenic growth peptide (OGP) receptor for secondary hyperparathyroidism (SHPT) treatment.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56436\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines Licenses Micot\u2019s MT1013 for Secondary Hyperparathyroidism in $178M Deal\" \/>\n<meta property=\"og:description\" content=\"Everest Medicines Limited (HKG: 1952) announced a licensing agreement with Micot, a polypeptide NME drug developer, securing exclusive commercialization rights to MT1013 in China and the Asia\u2011Pacific region (excluding Japan). The first\u2011in\u2011class dual\u2011target peptide targets calcium\u2011sensing receptor (CaSR) and osteogenic growth peptide (OGP) receptor for secondary hyperparathyroidism (SHPT) treatment.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56436\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-05T13:08:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-05T13:08:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56436#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56436\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines Licenses Micot\u2019s MT1013 for Secondary Hyperparathyroidism in $178M Deal\",\"datePublished\":\"2026-02-05T13:08:39+00:00\",\"dateModified\":\"2026-02-05T13:08:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56436\"},\"wordCount\":332,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Everest Medicines\",\"HKG: 1952\",\"Micot Pharmaceutical Technology\",\"Potential first-in-class\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56436#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56436\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56436\",\"name\":\"Everest Medicines Licenses Micot\u2019s MT1013 for Secondary Hyperparathyroidism in $178M Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-05T13:08:39+00:00\",\"dateModified\":\"2026-02-05T13:08:41+00:00\",\"description\":\"Everest Medicines Limited (HKG: 1952) announced a licensing agreement with Micot, a polypeptide NME drug developer, securing exclusive commercialization rights to MT1013 in China and the Asia\u2011Pacific region (excluding Japan). The first\u2011in\u2011class dual\u2011target peptide targets calcium\u2011sensing receptor (CaSR) and osteogenic growth peptide (OGP) receptor for secondary hyperparathyroidism (SHPT) treatment.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56436#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56436\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56436#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines Licenses Micot\u2019s MT1013 for Secondary Hyperparathyroidism in $178M Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines Licenses Micot\u2019s MT1013 for Secondary Hyperparathyroidism in $178M Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Everest Medicines Limited (HKG: 1952) announced a licensing agreement with Micot, a polypeptide NME drug developer, securing exclusive commercialization rights to MT1013 in China and the Asia\u2011Pacific region (excluding Japan). The first\u2011in\u2011class dual\u2011target peptide targets calcium\u2011sensing receptor (CaSR) and osteogenic growth peptide (OGP) receptor for secondary hyperparathyroidism (SHPT) treatment.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56436","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines Licenses Micot\u2019s MT1013 for Secondary Hyperparathyroidism in $178M Deal","og_description":"Everest Medicines Limited (HKG: 1952) announced a licensing agreement with Micot, a polypeptide NME drug developer, securing exclusive commercialization rights to MT1013 in China and the Asia\u2011Pacific region (excluding Japan). The first\u2011in\u2011class dual\u2011target peptide targets calcium\u2011sensing receptor (CaSR) and osteogenic growth peptide (OGP) receptor for secondary hyperparathyroidism (SHPT) treatment.","og_url":"https:\/\/flcube.com\/?p=56436","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-05T13:08:39+00:00","article_modified_time":"2026-02-05T13:08:41+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56436#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56436"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines Licenses Micot\u2019s MT1013 for Secondary Hyperparathyroidism in $178M Deal","datePublished":"2026-02-05T13:08:39+00:00","dateModified":"2026-02-05T13:08:41+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56436"},"wordCount":332,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Everest Medicines","HKG: 1952","Micot Pharmaceutical Technology","Potential first-in-class"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56436#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56436","url":"https:\/\/flcube.com\/?p=56436","name":"Everest Medicines Licenses Micot\u2019s MT1013 for Secondary Hyperparathyroidism in $178M Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-05T13:08:39+00:00","dateModified":"2026-02-05T13:08:41+00:00","description":"Everest Medicines Limited (HKG: 1952) announced a licensing agreement with Micot, a polypeptide NME drug developer, securing exclusive commercialization rights to MT1013 in China and the Asia\u2011Pacific region (excluding Japan). The first\u2011in\u2011class dual\u2011target peptide targets calcium\u2011sensing receptor (CaSR) and osteogenic growth peptide (OGP) receptor for secondary hyperparathyroidism (SHPT) treatment.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56436#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56436"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56436#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines Licenses Micot\u2019s MT1013 for Secondary Hyperparathyroidism in $178M Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56436"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56436\/revisions"}],"predecessor-version":[{"id":56438,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56436\/revisions\/56438"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}